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The use of isolated lung transplantation without con-comitant heart transplantation was initially applied
to patients with the diagnosis of pulmonary fibrosis.
The preliminary report of the Toronto Lung Trans-
plantation Group described two cases of successful sin-
gle lung transplantation for end-stage pulmonary fibro-
sis.1 A subsequent report from the Toronto group
described results after single lung transplantation for 20
patients with fibrotic lung diseases, including idiopath-
ic pulmonary fibrosis (IPF), sarcoidosis, eosinophilic
granuloma, and pulmonary fibrosis caused by chemo-
therapeutic drugs.2 The Toronto group experienced a
perioperative mortality of 20% and a 1-year survival of
Objective: Between July 1988 and July 1998, we performed 433 lung trans-
plants. Forty-five patients had idiopathic pulmonary fibrosis, and operations
for these patients included 32 single lung transplants and 13 bilateral sequen-
tial lung transplants. This study reviews this experience and compares single
lung transplantation and bilateral lung transplantation for pulmonary fibrosis.
Methods: We performed a retrospective review, including inpatient hospital
charts, outpatient clinic records, and telephone contact with patients to veri-
fy current health status.
Results: Perioperative mortality was 4 (8.9%) patients. One patient under-
went redo bilateral lung transplantation for reperfusion injury and graft fail-
ure after single lung transplantation. The median hospitalization was 22
days. Actuarial survival at 1 and 5 years was 75.5% and 53.5%, respective-
ly, which was not significantly different from our survival for all recipients
(85.5% and 56.4%, respectively). Seventeen (41%) of 41 operative survivors
have died. Late causes of death included obliterative bronchiolitis with res-
piratory failure (9), malignancy (3), and cytomegalovirus pneumonitis (2).
Hospital mortality was 3 (9.4%) of 32 after single lung transplantation and 1
(7.7%) of 13 after bilateral lung transplantation. There was no difference
between single and bilateral lung transplantation with regard to hospital stay.
Four (12.5%) of the 32 patients undergoing single lung transplantation
required tracheostomy, whereas 3 (23%) of 13 recipients undergoing bilater-
al lung transplantation required tracheostomy.
Conclusion: Single or bilateral lung transplantations offer viable therapy for
patients with pulmonary fibrosis. We demonstrate no benefit of bilateral over
single lung transplantation for patients with this diagnosis. Survival after
transplantation appears better than that of historic control subjects receiving
standard medical care at other institutions. (J Thorac Cardiovasc Surg
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45%, which at the time represented major advances.
The choice of pulmonary fibrosis as the first disease to
be treated with isolated lung transplantation was not
random; it was selected with the thought that restrictive
pulmonary function and the moderately elevated pul-
monary vascular resistance would lead to selective ven-
tilation and perfusion of the graft lung. Transplantation
has subsequently been applied more broadly to other
end-stage lung diseases, but IPF remains the second
most frequent diagnosis leading to transplantation
according to the Fifteenth Report delivered in July
1998 by the International Society of Heart and Lung
Transplantation. Emphysema and α1-antitrypsin defi-
ciency emphysema together accounted for 55% of
transplants, with IPF next at 20.9% of transplants.3 The
current report is a review of our institutional experience
with lung transplantation, specifically for IPF. An effort
is made to compare the results obtained with single and
bilateral transplantation in patients with pulmonary
fibrosis.
Patients and methods
We performed a retrospective review of all patients receiv-
ing single or bilateral lung transplantation from the start of
our lung transplant program in July 1988 until July 1998.
During that period, 433 transplants were performed, includ-
ing 55 transplants in 54 recipients for fibrotic lung disease.
These patients included 45 patients with IPF, 5 patients with
sarcoidosis, 2 patients with bleomycin toxicity, and 1 patient
each with eosinophilic granuloma and silicosis. This report
describes the experience with the 45 patients undergoing
transplantation for IPF.
Statistical methods. All normally distributed continuous
data (eg, forced expiratory volume in 1 second [FEV1] and age)
are expressed as means ± SD. Two group comparisons of nor-
mally distributed continuous data are made by means of the
unpaired t test. Nonnormally distributed data (ie, postoperative
hospital stay) are expressed as median and interquartile (25%-
75%) range. Two-group comparisons in these data sets are made
with the Mann-Whitney U statistic. The combined effects of
time and type of procedure on repeated measurements of phys-
iologic function were analyzed by use of the Mixed Procedure
(PROC MIXED) in SAS version 7 (SAS Institute, Inc, Cary,
NC). Survival estimates were calculated with the Kaplan-Meier
method. Comparison of survival of different groups of patients
is done with the Mantel-Haenszel test. Tabular data are com-
pared by the Fisher exact test. A multivariate Cox regression
analysis was used to test the effect of the variables described in
Table I on overall survival. With the exception of the PROC
MIXED test, data analysis was performed by means of SYS-
TAT version 7.0 (SYSTAT, Inc, Evanston, Ill).
Recipient selection. The selection of recipients for lung
transplant has become a relatively standard process, and
selection criteria have been described in previous publica-
tions.4-6 In brief, patients are selected when they have dis-
abling lung disease with a limited prognosis and no other sys-
temic illness that would complicate or be complicated by
lung transplantation and immunosuppression. In contrast to
those with obstructive physiology, patients with pulmonary
fibrosis whose condition has deteriorated to the point of
necessitating transplantation generally have a rapid downhill
course. Relative indications for early referral for transplanta-
tion include resting hypoxemia, worsening desaturation with
exercise despite supplementary oxygen, failure to respond to
medical therapy, and a decreasing trend in sequential mea-
surements of vital capacity.
Procedure selection. In our earliest experience, single
lung transplant was the only procedure offered, and its appli-
cation was limited to patients free of pulmonary sepsis or
cavitary disease. When bilateral lung transplantation became
increasingly reliable, this alternative was also offered to
patients with IPF. Since that time, we have been performing
either single or bilateral transplants, with the decision based
primarily on organ availability. Barring any specific anatom-
ic constraints, patients will generally be listed for “either or
both,” indicating a willingness to accept a single graft for
either the right or left lung or a bilateral graft. Single lung
transplants have remained more common, despite our will-
ingness to perform a bilateral procedure, presumably because
of the increased availability of single lung grafts and the lack
of any evidence for the superiority of the bilateral transplan-
tation in this disease.
Preoperative treatment. Once patients are listed for lung
transplantation, efforts are made to optimize their medical
care to enhance survival and function while on the organ
waiting list. For all patients, this involves enrollment and
active participation in pulmonary rehabilitation. Adjustment
of medications may include weaning of steroids to minimize
the complications of corticosteroids during the time spent on
the waiting list for donor lungs. Preoperative therapy ranges
from ensuring continued compliance with pulmonary reha-
bilitation to acute management, including intubation and
intensive care when deterioration occurs during the waiting
period. Although patients will generally not be listed if they
are intubated, patients who decline after listing for transplan-
tation are still considered if their general health is otherwise
compatible with postoperative recovery from a transplant
operation.
Donor selection. The criteria for lung donors are well
established and are applied to pulmonary fibrotic recipients,
just as they are to patients with other diagnoses. Our donor
lung selection criteria and our operative techniques for lung
procurement have recently been reviewed.7 Specific modifi-
cations for recipients with pulmonary fibrosis occur mainly
with regard to the size of acceptable donor lungs. For exam-
ple, when planning a lung transplantation for obstructive lung
disease, we attempt to place allografts with 15% to 20%
greater volume than the recipient’s predicted lung volume.
Implantation of such a large allograft is easily achieved in a
patient with obstructive lung disease because the recipient
pleural space may be two or more times the predicted vol-
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ume. The restrictive nature of pulmonary fibrosis causes the
lungs and pleural spaces to be markedly reduced in size. It is
therefore inadvisable to oversize these patients to an exces-
sive degree. For bilateral lung replacement, we prefer to
match the donor lung volumes to the predicted normal lung
volume. A bilateral transplant with oversized donor lungs for
a recipient with pulmonary fibrosis may produce hemody-
namic difficulties at the termination of the procedure.
Operative techniques. Our current operative technique
has been described in previous publications.8 Single lung
transplantation is generally performed through a posterolater-
al thoracotomy, and the technique has varied little over the
time span of this report. The lung chosen for replacement is
resected, and the donor lung is implanted, generally without
the need for cardiopulmonary bypass. Bilateral lung trans-
plantation has been typically performed through a clamshell
incision consisting of bilateral anterolateral thoracotomies
with transverse division of the sternum to allow maximal
exposure.9 For the past 3 years, we have been omitting the
sternal division in an effort to avoid the major and minor
complications commonly encountered with sternal division
and subsequent closure.10 The use of omentum to wrap the
bronchial anastomosis was limited to the earliest fraction of
the patients described in this report. Cardiopulmonary bypass
was used on an individualized basis in cases of concomitant
pulmonary hypertension or when hypoxemia or hypercarbia
would not allow single lung ventilation during the implanta-
tion of the first lung. The IPF recipients pose challenges on
implantation because of their diminished chest volumes and
the difficulty in maintaining adequate topical hypothermia
with iced saline slush during surgery. The use of malleable
retractors to depress the diaphragm during implantation has
partially overcome this problem.
Postoperative care. Early postoperative care occurs in the
intensive care unit, with mechanical ventilation and invasive
cardiac monitoring. We routinely extubate patients as soon as
standard weaning criteria are met. A flexible bronchoscope is
used at the time of extubation and again 7 to 10 days after
transplantation. Immunosuppression consists initially of
cyclosporine (INN: ciclosporin), corticosteroids, and azathio-
prine, with the addition of antithymocyte globulin during the
first several postoperative days.5 As might be expected, the
management of acute rejection has changed dramatically
over the period of these observations. The early experience
was marked by frequent empiric boluses of intravenous cor-
ticosteroids based on clinical parameters, such as fever,
hypoxemia, and pulmonary infiltrates. The recent practice is
more objective and guided by transbronchial biopsies to
accurately diagnose rejection before intensifying the
immunosuppression. Similarly, prevention and treatment of
cytomegalovirus (CMV) infection has been streamlined in
the 10 years that constitute this experience. It is our current
practice that recipients negative for CMV receiving CMV-
positive grafts receive prophylactic ganciclovir intravenously
for 6 weeks postoperatively.
Results
Demographics.  We performed 46 transplants in 45
patients with fibrotic lung disease from July 1988 to
July 1998. The demographic and physiologic charac-
teristics of these patients are described in Table I. There
was no significant preoperative difference between
patients given single lung transplants and patients
given bilateral lung transplants when compared accord-
ing to sex distribution, age, or functional status as
described by oxygen use, FEV1, forced vital capacity,
and 6-minute walk distance.
Donor lung characteristics.  Using criteria de-
scribed in a previous publication,11 we classified donor
lungs as either ideal or marginal. The lungs implanted
in this series were deemed ideal in 37 cases and mar-
ginal in 10 cases. Marginal lungs were only used when
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Table I. Lung transplant recipients with pulmonary fibrosis
All Bilateral Single P value
Sex
Female 19 6 13 .8
Male 26 7 19
Age (y) 49.5 ± 10 52.9 ± 8.7 48.8 ± 9.1 .1
Preoperative oxygen (L/min)
At rest 4.7 ± 3.6 6.0 ± 5.1 4.2 ± 2.9 .2
At exercise 7.2 ± 3.4 7.7 ± 4.3 7.0 ± 3.1 .6
Six-minute walk (ft) 859 ± 328 994 ± 285 804 ± 332 .06
FEV1 (L) 1.54 ± 0.61 1.7 ± 0.8 1.47 ± 0.5 .4
FVC (L) 1.95 ± 0.87 2.21 ± 0.99 1.84 ± 0.81 .2
Ischemic time
Right lung 282 ± 64 267 ± 73 289 ± 58 .8
Left lung 290 ± 72 291 ± 91 290 ± 65 .97
Operative time (h) 5.4 ± 2.0 6.1 ± 1.9 5.1 ± 1.8 .1
CPB use 8 (17%) 6 (46%) 2 (6%) .01
FVC, Forced vital capacity; CPB, cardiopulmonary bypass.
the transplant was bilateral. Thirty-six lung grafts were
procured at a distance from St Louis, which required air
travel to allow timely procurement and return, whereas
11 donors were local. In 32 cases the procurement was
performed by a member of our operative team, where-
as the other 15 procurements were performed by other
teams in the course of retrieving the contralateral lung
or the heart. The mean ischemic times were 263 min-
utes for right lungs and 290 minutes for left lungs.
Recipient operation. There were no intraoperative
deaths. The mean length of operation was 5.4 hours.
Eight patients required cardiopulmonary bypass, and
one patient had such severe immediate reperfusion
injury that weaning from bypass proved impossible,
and the patient was maintained on extracorporeal mem-
brane oxygenation postoperatively. Operative times and
ischemic times were similar for the patients receiving
single and bilateral transplants. There was a statistical-
ly significant difference in the frequency of use of car-
diopulmonary bypass, with bypass being used in 6
(46%) of 13 of the bilateral transplants and only 2 (6%)
of 32 of the single lung transplants. The number of
transplants per year and the ratio of single/bilateral
transplants have remained stable throughout the studied
time period.
Postoperative results. The summary of early hemo-
dynamic measurements appears in Table II. There was
an immediate fall in the pulmonary vascular resistance,
but all hemodynamic changes were mild in magnitude
and failed to reach statistical significance. This analy-
sis is prone to bias because the typical patient doing
well postoperatively will have a low pulmonary artery
pressure, low pulmonary vascular resistance, and high
cardiac output. This good function will lead to removal
of the pulmonary artery catheter and cause later obser-
vations to be weighted in the direction of the poorly
performing patients. Four patients, all male subjects,
were considered operative deaths. Causes of death
included an anastomotic dehiscence leading to death on
postoperative day 37, primary graft failure and rejec-
tion causing death on postoperative day 33, sepsis and
ischemic bowel with death on postoperative day 37,
and primary graft failure and renal failure with death on
postoperative day 9 despite retransplantation. The fre-
quency of adverse events in single and bilateral trans-
plant recipients are displayed in Table III. Forty-one
patients survived the operation and were discharged
from the hospital. Some details regarding the length of
hospitalization are recorded in Table IV. When single
lung transplantation and bilateral lung transplantation
for IPF were compared, there was no significant differ-
ence in the length of hospitalization or in the preva-
lence of adverse events encountered postoperatively.
Functional results for the hospital survivors are shown
in Figs 1 and 2 and were analyzed for statistical signif-
icance by means of the mixed procedure described in
the “Statistical methods” section of the article. As
demonstrated in Fig 1, the FEV1 data show a statistical-
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Table II. Early postoperative hemodynamics
No. evaluated
Evaluation Immediate postop 24 hours postop 72 hours postop
(n = 41) (n = 39) (n = 39) (n = 14)
Mean PA (mm Hg) 23.3 ± 7.4 26.0 ± 7.7 (P = .2) 23.9 ± 6.5 (P = .8) 27.2 ± 7.0 (P = .8)
PVR (dyne/[s · cm5]) 239 ± 96 215 ± 85 (P = .03) 205 ± 76 (P = .03) 205 ± 76 (P = .1)
CO (L/min) 5.24 ± 1.0 5.51 ± 1.7 (P = .97) 5.64 ± 1.6 (P = .7) 5.32 ± 1.6 (P = .2)
PA, Pulmonary artery pressure; PVR, pulmonary vascular resistance; CO, cardiac output.
Table III. Frequency of adverse events by procedure type
Single lung transplant (n = 32) Bilateral lung transplant (n = 13)
Event No. of patients % CI No. of patients % CI P value
Death 3 9 3-21 1 8 1-30 1.00
BOS 13 41 27-55 6 46 25-70 .8
Airway 3 9 3-21 1 8 1-30 1.00
Tracheostomy 4 13 4-25 3 23 8-47 .4
P value calculated with the Fisher exact test.
Death, In-hospital mortality; CI, confidence interval; BOS, development of bronchiolitis obliterans syndrome; airway, development of airway stricture requiring sur-
gical or bronchoscopic treatment; tracheostomy, tracheostomy performed during initial hospitalization.
ly significant time effect over the period of observation
(P < .0001). There is no significant difference when the
patients are compared according to type of transplant (P
= .088) and no interaction between time and type of
transplant (P = .7). Similarly, Fig 2 shows the distances
traveled in a 6-minute walk over various intervals from
the time of transplantation. The 6-minute walk distances
show a statistically significant change over time (P <
.0001) after transplantation, which is not significantly
different between single and bilateral recipients (P =
.37). When individual intervals between evaluation and
follow-up measurement were assessed with the same
statistical tool (ie, evaluation to 3 months and evaluation
to 12 months), none of the specific interval changes for
either FEV1 or 6-minute walk distance were statistical-
ly significant. Similar findings were noted in other mea-
sured indicators of function, including forced vital
capacity and room air arterial blood gasses.
Long-term survival was calculated by means of
Kaplan-Meier survival estimates. Fig 3 shows the sur-
vival of the 45 patients displayed as individual curves
for the single lung transplant and bilateral transplant
subgroups. There was no statistical difference between
the two curves (P = .42, Mantel-Haenszel log-rank
test). To test the hypothesis that patients with IPF are
more difficult to transplant successfully, we compared
the survival of the 45 patients with IPF with the sur-
vival of the other 395 patients whom we have subject-
ed to transplantation as of November 1998. These sur-
vival curves appear in Fig 4, and once again, there is no
statistical difference between the two curves (P = .20,
Mantel-Haenszel log-rank test). To evaluate the possi-
bility that higher risk patients had been inadvertently
clustered into one of the two groups, we performed a
multivariate Cox regression analysis on every preoper-
ative and perioperative variable described in Table I.
None of the variables were statistically significant pre-
dictors of survival. Late deaths have occurred in 17
patients, and the causes for these deaths are listed in
Table V. Bronchiolitis obliterans syndrome is the lead-
ing cause of late mortality. There has been no recur-
rence of pulmonary fibrosis in any allograft.
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Table IV. Postoperative hospital stay
All patients (n = 45) Bilateral (n = 13) Single (n = 32) P value
Postoperative hospital stay (d) 22 (14-33) 23 (15-39) 21 (13-32) .4
Mechanical ventilation (d) 3 (2-10) 4 (3-18) 3 (2-9) .5
Intensive care unit stay (d) 5 (4-12) 6 (4-12) 5 (3-10) .7
Values shown as median (25th-75th percentile); the 25th and 75th percentile values describe the range of values that contains half the subjects described. Lengths of
ventilation, hospitalization, and intensive care unit stay compared with the Mann-Whitney U test.
Fig 1. FEV1 in all patients receiving lung transplantation for pulmonary fibrosis. The solid line describes bilateral
transplant recipients, and the dotted line describes single lung transplant recipients. Error bars describe SEM. The
number of patients evaluated at each time interval is listed next to each curve.
Discussion
IPF is a subtype of a broad heterogeneous group of
lung disorders characterized by dyspnea, parenchymal
infiltrates, restrictive pulmonary physiology, and im-
paired gas exchange. IPF is the most common subtype
and is known as cryptogenic fibrosing alveolitis in the
United Kingdom and Europe. The diagnosis has
become increasingly specific in recent decades,
prompting some to call for restriction of the term in
such a way that IPF applies only to patients with
histopathologic or high-resolution computed tomo-
graphic evidence of “usual interstitial pneumonitis.”12
Such a restriction will describe a relatively uniform
group of patients with a progressive and generally fatal
disease with a median survival between 2 and 3 years.
Less-precise diagnostic classification will include
patients with other similar disorders with better prog-
noses and less-predictable downward courses.
The poor prognosis of patients with IPF is well
established. Harari and colleagues13 reported on the
actuarial survival of 43 patients with IPF referred for
transplantation who were comparable in many criteria
with the patients described in our report. By censoring
patients actually undergoing transplantation (treating
them as lost to follow-up at the time of transplanta-
tion), they observed a median survival of less than 10
months and a 2-year survival of 25% compared with
the median post-transplantation survival of 5 years
and a 2-year survival of 73% described in this report.
Such a comparison is hazardous; the medically treat-
ed patients included all patients with IPF listed for
transplantation, whereas the surgically treated
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Fig 2. Distance walked in a standard 6-minute walk test for all patients receiving lung transplantation for pul-
monary fibrosis. The solid line describes bilateral transplant recipients, and the dotted line describes single lung
transplant recipients. Error bars describe SEM. The number of patients evaluated at each time interval is listed next
to each curve.
Fig 3. Kaplan-Meier survival estimates for 45 patients undergoing transplantation for IPF from 1988 to 1998. Error
bars at each event represent 70% confidence intervals. Survival estimates for single lung transplantation (n = 32)
and bilateral lung transplantation (n = 13) were not statistically different when tested by using the Mantel-Haenszel
log-rank test (P = .42).
patients are the result of selection bias, which has
removed all patients too sick to survive on the waiting
list until donor lungs became available. Still, the high
mortality of medically treated patients at least pro-
vides a benchmark that makes the post-transplantation
median survival more meaningful.
Once the patient with IPF receives a transplant, there
is much evidence to suggest that the early post-trans-
plant course is more difficult than that seen for patients
with other underlying diagnoses. The first-year survival
of our patients with IPF is 75.5%, which is not statisti-
cally different from the 1-year survival of 85.5% seen
in our entire cohort of transplant recipients, excluding
patients with IPF. Similarly, the data reported to the
United Network for Organ Sharing (UNOS) describes
a 1-year survival of 74% for IPF recipients compared
with 82% for emphysema and 80.3% for cystic fibro-
sis.14 This difference in early outcome of our recipients
has been previously described by Davis and col-
leagues.15 In that report, 16 patients with IPF were
compared with 43 patients with emphysema and 24
patients with pulmonary hypertension. The patients
with IPF had the worst initial gas exchange, the highest
initial pulmonary artery pressures, the highest peak air-
way pressures, the longest ventilatory times, the
longest intensive care unit stays, and the highest tra-
cheostomy rates. Thus, it appears the conclusion of one
author that “no underlying disease in transplantation
poses the dramatic difficulties faced in association with
advanced pulmonary fibrosis” is an accurate observa-
tion.16 It is interesting to note, however, that the data
collected by the International Society for Heart and
Lung Transplantation (ISHLT) failed to single out IPF
as a risk factor for increased mortality at 1 year, and our
own data from the current report did not show a statis-
tical difference in survival between patients with and
without IPF. The ISHLT multivariate analysis of risk
factors for 1-year mortality after lung transplant
showed only primary pulmonary hypertension to have
an odds ratio for mortality greater than 1 (1.31). At the
other end of the spectrum, emphysema (0.48) and α1-
antitrypsin deficiency (0.74) had odds ratios of less
than 1. IPF did, however, fall out as having a greater
risk for 5-year mortality, with an odds ratio of 1.68
(confidence intervals, 1.16-2.43) and a P value of .01.3
Our data cannot support any claim of superiority for
bilateral transplantation over single lung transplanta-
tion. There was no functional difference as measured
by 6-minute walk distance and FEV1, and the differ-
ences in survival between the groups did not reach sta-
tistical significance. This can be added to other reports
with similar conclusions regarding the single-versus-
bilateral debate for emphysema17-19 and for pulmonary
hypertension.20 Such a simple comparison can be mis-
leading, though. For instance, in transplants performed
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Fig 4. Kaplan-Meier survival estimates for 45 patients undergoing transplantation for IPF and 395 patients undergoing
transplantation for all other diagnoses from 1988 to 1998. Error bars at each event represent 70% confidence intervals.
Survival curves were not statistically different when tested by using the Mantel-Haenszel log-rank test (P = .20).
Table V. Causes of death
Cause of death No. of patients
Hospital perioperative mortality 4
Multisystem organ failure 2
Massive pulmonary hemorrhage 1
Adult respiratory distress syndrome 1
Bronchiolitis obliterans syndrome 10
Infection 3
Sepsis syndrome 1
CMV pneumonia 2
Malignancy 3
Lung cancer 2
Lymphoma 1
Myocardial infarction 1
Total deaths 21
for diagnoses that allow either single or bilateral grafts,
the preoperative plan to perform a bilateral transplant
may be altered intraoperatively on the basis of the dif-
ficulty of the dissection or the discovery of severe
reperfusion injury on unclamping the hilum of the first
graft. Such a decision may be lifesaving for the patient,
leaving behind a native lung that acts as a buffer for the
poor initial function of the graft lung, yet the practice
will bias retrospective analysis against single lung
transplantation by including all such complicated
patients in the single lung transplantation group. With
respect to our data, the preponderance of left single
lung transplants in this report (24 left vs 8 right) raises
some questions and is not easily explained.
In summary, our data show that patients with IPF can
undergo successful transplantation with an operative
mortality of less than 10%. Median survival in excess of
5 years is possible, and functional improvement, as mea-
sured by spirometry, diffusing capacity, and 6-minute
walk distance, is immediate and sustained. The timing of
referral becomes increasing crucial for patients with IPF
as the waiting times for donor lungs lengthen because
many cohorts of patients with IPF reported in the litera-
ture have median survivals that are similar to the current
mean waiting times experienced on the transplant list.
Even with existing waiting lists, nearly 33% of patients
with IPF die on the waiting list, whereas another 10% are
removed from the list, many because of deterioration to
a state no longer considered amenable to transplanta-
tion.21 International guidelines for referral for transplan-
tation include “symptomatic, progressive disease with
failure to improve or maintain on medical therapy.”6
Because it is estimated that 70% to 90% of patients with
true IPF will fail to respond to medical treatment,12,22,23
early referral for transplantation is urged when patients
with IPF become symptomatic. Finally, the question of
whether a single or bilateral transplant is most appropri-
ate for IPF remains incompletely answered. The full
answer to this question will likely require pooled data
from the UNOS or the ISHLT to answer.
We acknowledge the assistance provided by Kim Trinkaus
and Paul Thompson, PhD, in the statistical analysis of this
work.
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Discussion
Dr R. Morton Bolman III (Minneapolis, Minn). The
manuscript makes several important points, as does the pre-
sentation. The authors have been very careful to limit their
analysis to patients with IPF, and that is what our medical
colleagues are doing as well, so that they can truly determine
whether transplantation compares with best current medical
therapy.
Several important points are made. First, at the authors’
institution, transplantation for IPF can offer improved sur-
vival compared with the best current medical therapy, with a
median survival of 5 years in the authors’ study compared
with 10 months with current medical therapy at an acceptable
operative risk of under 9%. These are outstanding data.
Second, there seems to be no advantage to bilateral over
single lung transplantation for these patients, and this con-
firms the common practice of single lung transplantation for
IPF around the world.
Our own experience, very briefly, in lung transplantation at
the University of Minnesota over the past 10 years is slightly
less encouraging than the data of the Washington University
group. We have performed transplantation in 300 patients, of
whom 27 had IPF. Similar to the authors’ experience, survival
at 1 year was indistinguishable from that of patients undergo-
ing transplantation for other diagnoses; however, at 2 years
and beyond, survival for IPF was statistically less than that
for other diagnoses, and 55% of our patients currently are
dead. Median survival is only 34 months compared with the
5 years in your study.
Your report is very encouraging; however, survival in your
own study for IPF is less at 1 year, and in the data from the
ISHLT survival is less for patients with IPF, although not sta-
tistically so. A previous report from your own institution
details the difficulties of transplantation in these patients. In
light of this information, and also recent data from the reg-
istry of the ISHLT demonstrating that IPF is indeed a risk fac-
tor for 5-year mortality, I have two questions for you.
Given the acknowledged lower survival, at least in UNOS
data and in data from our centers and others, can we justify
giving these patients 90 days of extra advantage on the wait-
ing list when they are placed on the list for transplantation? Is
this truly in the best interest of achieving the best overall out-
comes from a limited resource, namely scarce donor lungs?
Second, tracheostomy was required in roughly 15% of your
patients. Can you comment on this and compare it with your
incidence in patients without IPF? Also, could you tell us
when to recommend tracheostomy after lung transplantation
and describe your indications?
Again, I would like to congratulate you on a truly fine pre-
sentation and another important contribution from the
Washington University group to the field of lung transplanta-
tion. 
Dr Meyers. Thank you for your comments. With regard to
the first question: Can we justify adding 90 days to the wait-
ing time for patients with IPF in light of their lower survival
overall? I would turn it around and answer that you might
want to add more time because my impression is that the
patients with pulmonary fibrosis who actually reach the end
of the pipeline and are eligible for donor lung allocation are
more depleted and are less fit candidates for transplantation
than patients with other diagnoses who are far more stable on
the waiting list. Therefore, I think that from my observations,
justification is there for the additional 90 days, and one could
even consider adding time to this group of patients who expe-
rience a more rapid decline than patients with chronic
obstructive pulmonary disease.
With regard to the tracheostomy question, I do not have
data for comparison on the rate of tracheostomy insertion in
patients with IPF versus our other patients. Our general phi-
losophy is that if patients cannot be extubated in the first 6 or
7 days after transplantation, a tracheostomy will assist with a
more gradual and controlled wean from the ventilator.
Therefore, usually, if we can extubate them within the first
week, then they avoid a tracheostomy.
We have had some patients, particularly patients with IPF,
who have deteriorated on the waiting list and who were not
intubated by the time of listing but were intubated at the time
of transplantation, and those patients are at more risk for
long-term failure to wean and have a higher rate of tra-
cheostomy. 
Dr Scott J. Swanson (Boston, Mass). Given your results,
can you tell us now when you consider a double lung trans-
plant for IPF versus a single lung transplant?
Dr Meyers. In our program the consideration between a
single lung transplant or a bilateral lung transplant goes
beyond the recipient diagnosis. We have tried to cultivate a
reputation in our Organ Procurement Organization of our
willingness to accept lung grafts that might not be suitable for
single lung transplantation but would be reasonable for a
bilateral operation. In those situations we will often get a pair
of lungs and perform a bilateral transplantation in patients
who could accept either a single or a bilateral transplant.
Basically, except in unusual circumstances, the type of oper-
ation is determined by the availability of the bilateral or sin-
gle lung grafts.
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